Inactive Instrument

China Biologic Products Holdings, Inc.

Equities

CBPO

KYG215151047

Biotechnology & Medical Research

China Biologic Products Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019

March 13, 2020 at 02:48 am IST

China Biologic Products Holdings, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was USD 503.744 million compared to USD 466.877 million a year ago. Operating income was USD 163.647 million compared to USD 146.172 million a year ago. Net income was USD 138.807 million compared to USD 128.056 million a year ago. Basic earnings per share was USD 3.55 compared to USD 3.54 a year ago. Diluted earnings per share was USD 3.53 compared to USD 3.53 a year ago.

Latest news about China Biologic Products Holdings, Inc.

China Biologic Products Holdings, Inc.(NasdaqGS:CBPO) dropped from S&P Global BMI Index	23/21/23	CI
China Biologic Products Holdings, Inc.(NasdaqGM:CBPO) dropped from FTSE All-World Index	23/21/23	CI
China Biologic Products Holdings, Inc.(NasdaqGS:CBPO) dropped from NASDAQ Biotechnology Index	20/21/20	CI
China Biologic Products Holdings, Inc.(NasdaqGM:) dropped from NASDAQ Composite Index	20/21/20	CI
Centurium Capital Management Ltd., CITIC Capital Partners Management Ltd., Parfield International Ltd., V-Sciences Investments Pte Ltd, Hillhouse Capital Management, Ltd. and Joseph Chow, Chairman and Chief Executive Officer of China Biologic Products Holdings, Inc. completed the acquisition of remaining 31.16% stake in China Biologic Products Holdings, Inc..	20/21/20	CI
China Biologic Products Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	30/21/30	CI
China Biologic Products : Q4 Profit, Revenue Rise from Year Ago	30/21/30	MT
China Biologic Products Holdings, Inc. Announces Resignation of Yue’e Zhang from the Board of Directors	08/21/08	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO completed the acquisition of 9.72% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited.	06/21/06	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO completed the acquisition of 2% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited.	05/21/05	CI
CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited.	30/20/30	CI
Transcript : China Biologic Products Holdings, Inc., Q3 2020 Earnings Call, Nov 25, 2020	25/20/25
China Biologic Products Holdings, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	25/20/25	CI
China Biologic Products : Q3 Adj. EPS Slips From Year-Ago Levels But Sales Climb Nearly 2%	25/20/25	MT
China Biologic Products : to Merge With CBPO Group in Going-Private Deal; Shares Gain Pre-Bell	19/20/19	MT
Centurium Capital Management Ltd., CITIC Capital Partners Management Ltd., Parfield International Ltd., V-Sciences Investments Pte Ltd, Hillhouse Capital Management, Ltd. and Joseph Chow entered into a definitive Agreement and Plan of Merger to acquire remaining 31.16% stake in China Biologic Products Holdings, Inc. for $1.6 billion.	19/20/19	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO entered into a share purchase agreement to acquire 9.72% stake in China Biologic Products Holdings, Inc. for approximately $450 million.	27/20/27	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO entered into a share purchase agreement to acquire 2% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited for $93 million.	27/20/27	CI
CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited for approximately $110 million.	27/20/27	CI
Transcript : China Biologic Products Holdings, Inc., Q2 2020 Earnings Call, Aug 18, 2020	18/20/18
China Biologic Products Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	18/20/18	CI
Transcript : China Biologic Products Holdings, Inc., Q1 2020 Earnings Call, May 21, 2020	21/20/21
China Biologic Products Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	21/20/21	CI
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction	21/20/21	CI
Hillhouse Capital Provides Information to Shareholders of China Biologic	09/20/09	CI

Chart China Biologic Products Holdings, Inc.

Duration

Period

Chart China Biologic Products Holdings, Inc.

More charts

Company Profile

China Biologic Products Holdings Inc is a China-based company. The Company operates as a biopharmaceutical company. The Company research, develop, and produces human plasma-based pharmaceutical and coagulation factor products in the form of tablets, injections, capsules, and syrups. Company also distributes pharmaceutical products. It serves clients in China.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs